DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at https://www.reginfo.gov/public/do/PRAMain. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

Table 1—List of Information Collections Approved by OMB

<table>
<thead>
<tr>
<th>Title of collection</th>
<th>OMB control No.</th>
<th>Date approval expires</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temporary Marketing Permit Applications</td>
<td>0910–0133</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Establishing and Maintaining Lists of U.S. Milk Product Manufacturers/Processors</td>
<td>0910–0509</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Channels of Trade Policy for Commodities with Residues of Pesticide Chemicals</td>
<td>0910–0562</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>revocable, suspended, or modified by the EPA</td>
<td>0910–0566</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Medical Devices; Exception from General Requirements for Informed Consent</td>
<td>0910–0586</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Exceptions or Alternatives to Labeling Requirements for Products Held by the</td>
<td>0910–0614</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Strategic Stockpile</td>
<td>0910–0686</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Additional Criteria and Procedures for Classifying Over-the-Counter Drugs</td>
<td>0910–0688</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>as Generally Recognized as Safe and Effective and Not Misbranded</td>
<td>0910–0769</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Electronic Submission of Allegations of Regulatory Misconduct Associated with</td>
<td>0910–0771</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Medical Devices</td>
<td>0910–0847</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Providing Waiver-Related Materials in Accordance With the Guidance for Industry on</td>
<td>0910–0133</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Providing Post-Market Periodic Safety Reports in the International Conference</td>
<td>0910–0509</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>on Harmonisation E2C(R2) Format</td>
<td>0910–0562</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Data To Support Social and Behavioral Research as Used by the Food and Drug</td>
<td>0910–0566</td>
<td>11/30/2020</td>
</tr>
<tr>
<td>Administration</td>
<td>0910–0566</td>
<td>11/30/2020</td>
</tr>
</tbody>
</table>

Dated: February 9, 2018.

Leslie Kux,
Associate Commissioner for Policy.

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Determination of Regulatory Review Period for Purposes of Patent Extension; SYLVANT

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for SYLVANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

DATES: Anyone with knowledge that any of the dates as published (see the SUPPLEMENTARY INFORMATION section) are incorrect may submit either electronic or written comments and ask for a redetermination by April 16, 2018. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 14, 2018. See “Petitions” in the SUPPLEMENTARY INFORMATION section for more information.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before April 16, 2018. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of April 16, 2018. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).
I. Background

The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100–670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product’s regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: a testing phase and an approval phase. For human biological products, the testing phase begins when the exemption to permit the clinical investigations of the human biological product becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human biological product and continues until FDA grants permission to market the human biological product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of USPTO may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA’s determination of the length of a regulatory review period for a human biological product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA has approved for marketing the human biological product SYLVANT (siltuximab). SYLVANT is indicated for the treatment of patients with multicentric Castleman’s disease who are human immunodeficiency virus negative and human herpesvirus-8 negative. Subsequent to this approval, the USPTO received patent term restoration applications for SYLVANT (U.S. Patent Nos. 7,612,182 and 7,291,721) from Janssen Biotech, Inc., and the USPTO requested FDA’s assistance in determining the patents’ eligibility for patent term restoration. In a letter dated October 30, 2015, FDA advised the USPTO that this human biological product had undergone a regulatory review period and that the approval of SYLVANT represented the first permitted commercial marketing or use of the product. Thereafter, the USPTO requested that FDA determine the product’s regulatory review period.

II. Determination of Regulatory Review Period

FBA has determined that the applicable regulatory review period for SYLVANT is 3,747 days. Of this time, 3,510 days occurred during the testing phase of the regulatory review period, while 237 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(i)) became effective: January 21, 2004. The applicant claims January 8, 2004, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was January 21, 2004, which was 30 days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human biologic product under section 351 of the Public Health Service Act (42 U.S.C. 262): August 30, 2013. FDA has verified the applicant’s claim that the biologic license application (BLA) for SYLVANT (BLA 125496/0) was initially submitted on August 30, 2013.

3. The date the application was approved: April 23, 2014. FDA has verified the applicant’s claim that BLA 125496/0 was approved on April 23, 2014.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the USPTO applies several statutory limitations in its calculations of the actual period for patent extension. In its applications for patent extension, this applicant seeks 936 or 1,300 days of patent term extension.

III. Petitions

Anyone with knowledge that any of the dates as published are incorrect may submit either electronic or written comments and, under 21 CFR 60.24, ask for a redetermination (see DATES). Furthermore, as specified in §60.30 (21 CFR 60.24, ask for a redetermination (see DATES).
CFR 60.30), any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must comply with all the requirements of § 60.30, including but not limited to: Must be timely (see DATES), must be filed in accordance with § 10.20, must contain sufficient facts to merit an FDA investigation, and must certify that a true and complete copy of the petition has been served upon the patent applicant. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41–42, 1984.)

Petitions should be in the format specified in 21 CFR 10.30.

Submit petitions electronically to https://www.regulations.gov at Docket No. FDA–2013–S–0610. Submit written petitions (two copies are required) to the Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Dated: February 9, 2018.

Leslie Kux,
Associate Commissioner for Policy.

For written/paper comments only as a written/paper submission: To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with § 10.20 (21 CFR 10.20) and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

For further information contact:
Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration,